Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)

Detalles Bibliográficos
Autor principal: Lee, Byung-Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2013
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689019/
https://www.ncbi.nlm.nih.gov/pubmed/23807925
http://dx.doi.org/10.4093/dmj.2013.37.3.212
_version_ 1782274218081124352
author Lee, Byung-Wan
author_facet Lee, Byung-Wan
author_sort Lee, Byung-Wan
collection PubMed
description
format Online
Article
Text
id pubmed-3689019
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Korean Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-36890192013-06-27 Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24) Lee, Byung-Wan Diabetes Metab J Letter Korean Diabetes Association 2013-06 2013-06-14 /pmc/articles/PMC3689019/ /pubmed/23807925 http://dx.doi.org/10.4093/dmj.2013.37.3.212 Text en Copyright © 2013 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter
Lee, Byung-Wan
Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)
title Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)
title_full Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)
title_fullStr Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)
title_full_unstemmed Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)
title_short Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)
title_sort letter: efficacy and safety of biphasic insulin aspart 30/70 in type 2 diabetes suboptimally controlled on oral antidiabetic therapy in korea: a multicenter, open-label, single-arm study (diabetes metab j 2013;37:117-24)
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689019/
https://www.ncbi.nlm.nih.gov/pubmed/23807925
http://dx.doi.org/10.4093/dmj.2013.37.3.212
work_keys_str_mv AT leebyungwan letterefficacyandsafetyofbiphasicinsulinaspart3070intype2diabetessuboptimallycontrolledonoralantidiabetictherapyinkoreaamulticenteropenlabelsinglearmstudydiabetesmetabj20133711724

Ejemplares similares